Shire (NASDAQ:SHPG) released its earnings results on Wednesday. The biopharmaceutical company reported $3.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.86 by $0.12, Briefing.com reports. The firm had revenue of $4.15 billion for the quarter, compared to analyst estimates of $3.97 billion. Shire had a return on equity of 14.41% and a net margin of 10.95%. Shire’s revenue was up 8.9% compared to the same quarter last year. During the same period in the previous year, the company earned $3.37 earnings per share. Shire updated its FY18 guidance to $14.90-15.50 EPS.
Shire (SHPG) traded up $0.40 during trading hours on Wednesday, hitting $132.67. The company had a trading volume of 1,187,100 shares, compared to its average volume of 1,469,995. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.98 and a quick ratio of 0.52. Shire has a fifty-two week low of $123.73 and a fifty-two week high of $192.15. The firm has a market cap of $40,190.00, a price-to-earnings ratio of 25.08, a price-to-earnings-growth ratio of 0.71 and a beta of 1.41.
A number of research analysts recently issued reports on the company. Piper Jaffray Companies reaffirmed a “hold” rating on shares of Shire in a report on Wednesday, January 3rd. Cantor Fitzgerald set a $222.00 target price on Shire and gave the stock a “buy” rating in a report on Wednesday, January 3rd. Liberum Capital reaffirmed a “hold” rating on shares of Shire in a report on Wednesday, December 20th. Cowen set a $225.00 target price on Shire and gave the stock a “buy” rating in a report on Friday, January 5th. Finally, ValuEngine lowered Shire from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $212.50.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.